Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis
Peanut allergy in children can be life-threatening, with safe treatment options available. Now DBV Technologies in Paris has a phase III transdermal patch which desensitizes the patient to peanuts, with fast-track FDA approval.
The allergens in peanuts can stimulate an immune response to their presence, which can even result in life-threatening anaphylaxis (here is a great infographic demonstrating the reaction).
The Viaskin Peanut patch is the DBVs lead product candidate based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that can safely deliver biologically active compounds to the immune system through the immune cells of intact skin.
This means that small quantities of peanut allergens are allowed to be absorbed transdermally via the patch in a small built in air pocket where moisture condenses (permitting better absorption). Langerhans cells are attracted to the allergen in this outermost layer of the skin and transport it to the lymph nodes, where a gradual desensitization process can take place.
Now, the phase III safety and efficacy trial, dubbed the Peanut EPIT Efficacy and Safety Study (PEPITES), will enroll around 330 pediatric patients with peanut allergies to see if the Viaskin patch can really reduce these children’s reactivity to these allergens.
This is an exciting study, not just for DBV but also for sufferers of peanut allergies, for which there are no current treatment asides the pan-allergy epinephrine pen for emergencies. According to the CEO, Pierre-Henri Benhamou:
Over the last two decades, patients have been waiting for a treatment that could safely protect them against life-threatening anaphylaxis.Viaskin Peanut may be poised to be the first new therapy for safely treating peanut allergy”
So this is bit in the Immunotherapy field, and a possible end to peanut anaphylaxis is like the Holy Grail in Allergy research.
Feature Image Credit: The Viaskin Peanut Skin Patch (Source: DBV Technologies)
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.